Reports Q4 revenue $57.253M, consensus $56.21M. “Rhythm delivered solid IMCIVREE global sales growth and made continued progress developing therapies to address hyperphagia and severe obesity for people with rare MC4R pathway diseases in 2025,” said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm. “We enter 2026 focused on long-term growth and well-capitalized to achieve important commercial and clinical milestones. We are prepared to bring IMCIVREE to patients with acquired HO in the United States, pending FDA approval.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Shopify, eBay upgraded: Wall Street’s top analyst calls
- Rhythm Pharmaceuticals initiated with an Outperform at RBC Capital
- Rhythm’s LB54640 Trial Completion Sets Up Key Catalyst in Hypothalamic Obesity
- Rhythm Pharmaceuticals price target raised to $145 from $129 at Wells Fargo
- Rhythm Pharmaceuticals price target raised to $125 from $123 at H.C. Wainwright